it is my power point presentation of lymphoma for final year MBBS students,govt.medical college,kottayam
dr irshad ali k m
assistant professor,dept.of medicine,govt,medical college,kottayam
Lymphomas originate from cells of the lymphoid tissue. They are divided into Hodgkin's and non-Hodgkin's lymphomas. Hodgkin's lymphoma is characterized by the presence of Reed-Sternberg cells. It commonly presents with peripheral lymphadenopathy and B symptoms. Diagnosis involves biopsy and imaging. Staging involves the Ann Arbor or Cotswolds classification. Treatment involves chemotherapy, radiation therapy or a combination based on prognostic factors. Complications can include pneumonitis, cardiomyopathy, secondary cancers and gonadal dysfunction.
This document discusses lymphomas and leukemias. It defines them as malignant proliferations of white blood cells that can be liquid (leukemia) or solid (lymphoma). Lymphomas are classified as either Hodgkin's or non-Hodgkin's. Non-Hodgkin's lymphomas are further divided into peripheral or precursor B or T cell types. Hodgkin's disease is characterized by the presence of Reed-Sternberg cells. Common symptoms that can indicate lymphoma include swollen lymph nodes, unexplained fever, night sweats, fatigue, weight loss and itchy skin. Pathology can determine if a lymphoma is indolent or aggressive. Staging involves medical history, exams,
Lymphoma is cancer that arises in the lymphatic system. The lymphatic system contains lymph nodes and vessels that help fight infection and disease. There are two main types of lymphoma - Hodgkin's lymphoma and non-Hodgkin's lymphoma. Hodgkin's lymphoma is diagnosed using biopsies of swollen lymph nodes and contains abnormal B-cells called Reed-Sternberg cells. Non-Hodgkin's lymphoma can involve many types of abnormal white blood cells and can spread beyond lymph nodes. Both types are staged based on spread and tested using lymph node biopsies, imaging, and bone marrow samples. Treatment depends on type and stage but may include chemotherapy, radiation, and stem cell transplants
The document discusses myeloproliferative disorders (MPDs), which are clonal stem cell disorders characterized by increased blood cell counts and enlarged spleen and bone marrow. It focuses on chronic myeloid leukemia (CML), describing it as a MPD caused by a genetic mutation that results in uncontrolled white blood cell growth. CML progresses through chronic, accelerated, and blast phases, with symptoms ranging from fatigue to organ enlargement. Diagnosis involves blood and bone marrow tests detecting elevated white and platelet counts and the Philadelphia chromosome genetic abnormality associated with CML.
This document provides an overview of non-Hodgkin's lymphoma (NHL), including:
1. NHL is a heterogeneous group of malignant diseases of the lymphoid system that is defined and has varying epidemiology, classification, risk factors, pathogenesis, clinical features, investigations, and treatment.
2. NHL is classified in several systems, most recently the WHO system from 2008, which categorizes NHL into B-cell and T/NK-cell lymphomas that can be indolent or aggressive.
3. Specific subtypes like diffuse large B-cell lymphoma, follicular lymphoma, and Burkitt's lymphoma have unique characteristics and clinical presentations.
This document discusses white blood cell disorders, focusing on quantitative disorders of the white blood cells. It describes leukocytosis, which is an increased number of white blood cells, and leukopenia, which is a decreased number. The main types of leukocytosis and leukopenia discussed are neutrophilic leukocytosis, lymphocytosis, and eosinophilia. The causes, pathophysiology, and clinical features of each of these conditions are explained in detail.
This document discusses tumors of infancy and childhood. It begins by describing tumor-like lesions such as hamartomas and choristomas. It then discusses common benign tumors including hemangiomas, lymphangiomas, and sacrococcygeal teratomas. Malignant tumors that are discussed include leukemias, lymphomas, brain tumors, liver tumors, kidney tumors, soft tissue sarcomas, and bone tumors. Specific malignant tumors that are common in different age groups are also outlined. The document concludes by discussing characteristics of common childhood cancers like leukemia, lymphomas, brain tumors, and others.
This document discusses acute myeloid leukemia (AML) and its acute complications. It defines AML as a clonal expansion of myeloid precursor cells with reduced capacity to differentiate. Common clinical presentations include fever, bleeding, and fatigue due to excessive proliferation of myeloid cells in the bone marrow leading to pancytopenia. Two major acute complications discussed are leukostasis, which can cause pulmonary and neurological symptoms, and tumor lysis syndrome, which results in electrolyte abnormalities and renal impairment.
Lymphomas originate from cells of the lymphoid tissue. They are divided into Hodgkin's and non-Hodgkin's lymphomas. Hodgkin's lymphoma is characterized by the presence of Reed-Sternberg cells. It commonly presents with peripheral lymphadenopathy and B symptoms. Diagnosis involves biopsy and imaging. Staging involves the Ann Arbor or Cotswolds classification. Treatment involves chemotherapy, radiation therapy or a combination based on prognostic factors. Complications can include pneumonitis, cardiomyopathy, secondary cancers and gonadal dysfunction.
This document discusses lymphomas and leukemias. It defines them as malignant proliferations of white blood cells that can be liquid (leukemia) or solid (lymphoma). Lymphomas are classified as either Hodgkin's or non-Hodgkin's. Non-Hodgkin's lymphomas are further divided into peripheral or precursor B or T cell types. Hodgkin's disease is characterized by the presence of Reed-Sternberg cells. Common symptoms that can indicate lymphoma include swollen lymph nodes, unexplained fever, night sweats, fatigue, weight loss and itchy skin. Pathology can determine if a lymphoma is indolent or aggressive. Staging involves medical history, exams,
Lymphoma is cancer that arises in the lymphatic system. The lymphatic system contains lymph nodes and vessels that help fight infection and disease. There are two main types of lymphoma - Hodgkin's lymphoma and non-Hodgkin's lymphoma. Hodgkin's lymphoma is diagnosed using biopsies of swollen lymph nodes and contains abnormal B-cells called Reed-Sternberg cells. Non-Hodgkin's lymphoma can involve many types of abnormal white blood cells and can spread beyond lymph nodes. Both types are staged based on spread and tested using lymph node biopsies, imaging, and bone marrow samples. Treatment depends on type and stage but may include chemotherapy, radiation, and stem cell transplants
The document discusses myeloproliferative disorders (MPDs), which are clonal stem cell disorders characterized by increased blood cell counts and enlarged spleen and bone marrow. It focuses on chronic myeloid leukemia (CML), describing it as a MPD caused by a genetic mutation that results in uncontrolled white blood cell growth. CML progresses through chronic, accelerated, and blast phases, with symptoms ranging from fatigue to organ enlargement. Diagnosis involves blood and bone marrow tests detecting elevated white and platelet counts and the Philadelphia chromosome genetic abnormality associated with CML.
This document provides an overview of non-Hodgkin's lymphoma (NHL), including:
1. NHL is a heterogeneous group of malignant diseases of the lymphoid system that is defined and has varying epidemiology, classification, risk factors, pathogenesis, clinical features, investigations, and treatment.
2. NHL is classified in several systems, most recently the WHO system from 2008, which categorizes NHL into B-cell and T/NK-cell lymphomas that can be indolent or aggressive.
3. Specific subtypes like diffuse large B-cell lymphoma, follicular lymphoma, and Burkitt's lymphoma have unique characteristics and clinical presentations.
This document discusses white blood cell disorders, focusing on quantitative disorders of the white blood cells. It describes leukocytosis, which is an increased number of white blood cells, and leukopenia, which is a decreased number. The main types of leukocytosis and leukopenia discussed are neutrophilic leukocytosis, lymphocytosis, and eosinophilia. The causes, pathophysiology, and clinical features of each of these conditions are explained in detail.
This document discusses tumors of infancy and childhood. It begins by describing tumor-like lesions such as hamartomas and choristomas. It then discusses common benign tumors including hemangiomas, lymphangiomas, and sacrococcygeal teratomas. Malignant tumors that are discussed include leukemias, lymphomas, brain tumors, liver tumors, kidney tumors, soft tissue sarcomas, and bone tumors. Specific malignant tumors that are common in different age groups are also outlined. The document concludes by discussing characteristics of common childhood cancers like leukemia, lymphomas, brain tumors, and others.
This document discusses acute myeloid leukemia (AML) and its acute complications. It defines AML as a clonal expansion of myeloid precursor cells with reduced capacity to differentiate. Common clinical presentations include fever, bleeding, and fatigue due to excessive proliferation of myeloid cells in the bone marrow leading to pancytopenia. Two major acute complications discussed are leukostasis, which can cause pulmonary and neurological symptoms, and tumor lysis syndrome, which results in electrolyte abnormalities and renal impairment.
This document discusses Hodgkin's lymphoma and non-Hodgkin's lymphoma. It defines lymphomas as solid tumors of the lymphatic system that are divided into two main types: Hodgkin's lymphoma, characterized by Reed-Sternberg cells, and non-Hodgkin's lymphoma, which lacks these cells. Signs and symptoms, risk factors, investigations, staging, and treatment approaches are described for both types of lymphoma.
Key coagulation disorders covered in this document include hemophilia A caused by a factor VIII deficiency, hemophilia B from a factor IX deficiency, and von Willebrand disease where von Willebrand factor is defective
Non-Hodgkin's lymphomas are cancers that develop from lymphocytes. They are distinguished from Hodgkin's lymphoma by the absence of Reed-Sternberg cells. The cause is often genetic mutations or translocations that affect cell growth and survival. Symptoms depend on the type and location of the tumor. Biopsy and testing are needed for diagnosis and to classify the specific lymphoma. Treatment options include chemotherapy, radiation therapy, immunotherapy, and stem cell transplants. Prognosis depends on factors like tumor stage, grade, the patient's age and health. Common types of non-Hodgkin's lymphoma include diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
What is Lymphoma?
Malignant lymphoma is a term given to tumors of the lymphoid system and specifically of lymphocytes and their precursor cells
i.e.
Cancer of the lymphatic system.
Many lymphomas are known to be due to specific genetic mutations.
This document provides an overview of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). It discusses the definition, epidemiology, risk factors, signs/symptoms, diagnosis, classification, and treatment of HL. It also discusses the overview, epidemiology, etiology, classification, and treatment of several common subtypes of NHL, including follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. Treatment options discussed include chemotherapy regimens like ABVD, R-CHOP, radiotherapy, immunotherapy with rituximab, and newer targeted therapies.
Molecular pathology of lymphoma by dr ramesh Ramesh Purohit
Lymphoma classification is based on the cell of origin (B-cell, T-cell, NK-cell). Molecular biology techniques including immunophenotyping and genetic studies are important for accurate diagnosis and classification. Immunophenotyping uses cell surface markers identified by clusters of differentiation (CD markers) to determine the cell lineage and stage of differentiation. Common CD markers for B-cells, T-cells, myeloid cells and other lineages are described. Molecular studies can identify genetic abnormalities that help classify specific lymphoma subtypes. Together these molecular techniques provide crucial information beyond what is visible by microscopy alone.
Hodgkin's lymphoma accounts for about 30% of malignant lymphomas. It originates in the lymphatic system and was first described by Thomas Hodgkin in 1832. There are four main subtypes: nodular lymphocyte predominant, nodular sclerosing, mixed cellularity, and lymphocyte depleted. It typically presents as painless, enlarged lymph nodes and has a bimodal age distribution, most commonly affecting those aged 25-30 and over 55. Staging involves imaging such as CT and PET scans to determine the extent of disease. Treatment depends on the stage but commonly involves chemotherapy, radiation, or a combination. Prognosis is generally good even for advanced stages.
Hodgkin's lymphoma is a type of cancer that originates from white blood cells called lymphocytes. It is characterized by the presence of abnormal Reed-Sternberg cells in the lymph nodes and other tissues. There are two main classifications - classical Hodgkin's lymphoma, which has four subtypes based on the appearance of the lymph nodes, and nodular lymphocyte predominant Hodgkin's lymphoma. Signs and symptoms include enlarged lymph nodes, night sweats, weight loss, and fever. The cause is unknown but may involve abnormal B cells that do not die normally.
Von Willebrand disease is a bleeding disorder caused by low levels of the clotting protein von Willebrand factor. There are three main types of the disease - type 1 involves a small amount of von Willebrand factor present, type 2 involves normal levels but defects in function/structure, and type 3 involves no von Willebrand factor present. Symptoms include easy bruising, excessive bleeding, and heavy menstrual periods. The disease is usually inherited and testing involves bleeding time, factor VIII levels, and von Willebrand factor specific tests. Treatment focuses on avoiding aspirin/NSAIDs and using drugs like DDAVP or clotting factor replacements.
This document discusses hemostasis, bleeding disorders, and platelet disorders. It begins by explaining normal hemostasis and the mechanisms involved in maintaining a fluid blood state and forming clots at sites of injury. It then defines bleeding disorders as problems with blood clotting that result in abnormal bleeding. Common causes discussed include defects in blood vessels or blood itself, clotting factor deficiencies, platelet abnormalities, and liver disease. Finally, it examines several specific platelet disorders like thrombocytopenia, immune thrombocytopenic purpura, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, and those resulting from bone marrow infiltration or disseminated intravascular coagulation.
Identified in 1921 by James Ewing
2nd most common bone tumor in children
Ewing’s Sarcoma Family of tumors:
Ewing’s sarcoma (Bone –87%)
Extraosseous Ewing’s sarcoma (8%)
Peripheral PNET(5%)
Askin’s tumor
This document discusses neoplasms of hematopoietic tissue, specifically leukemias and lymphomas. It describes that leukemias can be acute or chronic based on cell maturity and type (myelogenous or lymphogenous). The main types of leukemia are further classified as acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. Lymphomas include Hodgkin's lymphoma characterized by Reed-Sternberg cells, and non-Hodgkin's lymphomas which originate from B cells, T cells, or histiocytes and can be low, intermediate, or high grade. Burkitt's lymphoma originates from B cells and can be endemic or sporadic
This document discusses coagulation disorders and provides information on hemophilia A, hemophilia B, and disseminated intravascular coagulation (DIC). It notes that hemophilia A is an X-linked bleeding disorder caused by a deficiency in coagulation factor VIII, while hemophilia B is caused by a deficiency in factor IX. Von Willebrand disease is described as the most common inherited bleeding disorder involving a quantitative or qualitative abnormality of von Willebrand factor. DIC is defined as an acquired syndrome characterized by systemic intravascular coagulation that can lead to thrombosis and bleeding complications.
This document summarizes quantitative and qualitative platelet disorders. The most common causes of abnormal bleeding are decreased platelet production, survival, or increased destruction/consumption. Disorders can be congenital or acquired and involve decreased megakaryocyte production, BM infiltration, ineffective thrombopoiesis, or disorders of thrombopoiesis control. Increased platelet destruction can be immunologic due to ITP, drugs, transfusion, or non-immunologic consumption. Functional platelet disorders involve adhesion, aggregation, or secretion defects which may be hereditary or acquired.
Non-Hodgkin's lymphoma is a cancer of the lymphatic system that can affect B-cells or T-cells. It is classified based on the type of cell and aggressiveness. Common symptoms include swollen lymph nodes, fever, night sweats, and unintended weight loss. While the exact causes are unknown, risk factors include chemical exposure, infections, and immunodeficiency. Diagnosis involves imaging tests and biopsy. Treatment options include chemotherapy, radiation, immunotherapy, and bone marrow transplants, with survival rates varying based on cell type and staging.
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature-appearing B lymphocytes in the blood, bone marrow, lymph nodes, and spleen. It is considered a clonal B cell malignancy caused by a defect in apoptosis that allows long-lived, non-cycling lymphocytes to accumulate over time. CLL cells typically express CD5, CD19, and CD23 and have mutations that dysregulate pathways controlling cell survival and apoptosis. Prognosis depends on clinical features and genetic abnormalities - deletion of 13q or mutated IgVH correlate with better prognosis while deletion of 11q or 17p indicate poorer prognosis. CLL can transform into an aggressive lymphoma called Richter's syndrome over time.
Acute leukemias are malignant disorders of hematopoietic tissues characterized by increased white blood cells in the bone marrow and blood. They are classified as either acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) based on the affected cell lineage. Treatment involves chemotherapy to induce remission through combination regimens, with the goals of restoring normal hematopoiesis and preventing relapse through additional consolidation therapy and long-term maintenance treatment. Prognosis depends on several risk factors like age, subtype, initial response to treatment, and specific genetic abnormalities.
1. The document discusses common benign and malignant pediatric tumors, including hemangiomas, neuroblastoma, Wilms tumor, and teratomas.
2. Neuroblastoma is the most common extracranial solid tumor in childhood and often presents as an abdominal mass, fever, or weight loss in children under 2.
3. Wilms tumor is the most common renal tumor of childhood, occurring mostly in ages 2-5, and may be associated with genetic syndromes like WAGR or Beckwith-Wiedemann syndrome.
Pathogenesis and treatment of Chronic Myeloid LeukemiaAlok Gupta
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome and BCR-ABL fusion gene. The natural history involves chronic, accelerated, and blast crisis phases if untreated. Tyrosine kinase inhibitors (TKIs) like imatinib revolutionized CML treatment by targeting BCR-ABL. TKIs induce high rates of response but resistance and intolerance occur in some patients. For these cases, second-generation TKIs or allogeneic stem cell transplant are recommended. Advanced phase CML has a poorer prognosis but TKIs can induce responses before transplant, which offers the best chance of cure.
This document provides information on chronic myelogenous leukemia (CML), including its definition, history, epidemiology, etiology, pathogenesis, clinical features, diagnosis, disease course, treatment, and more. Some key points:
- CML is a stem cell disease characterized by increased white blood cells, anemia, splenomegaly, and the Philadelphia chromosome.
- It has three phases: chronic, accelerated, and blast crisis. Treatment depends on the phase and may include tyrosine kinase inhibitors like imatinib, interferon, chemotherapy, and stem cell transplantation.
- The disease is caused by the BCR-ABL fusion gene which results in uncontrolled tyrosine kinase activity and increased proliferation of
Lymphoma is a cancer of lymphocytes. The most common place for abnormal lymphocytes is in lymph nodes (glands) particularly
under the arms, in the neck and in the groin.
Lymphoma is solid tumors of the immune system arising from cells of lymphoid tissues; lymphocytes, histiocytes, and reticulum cells. It can happen anywhere in the immune system, but usually in lymph nodes, spleen, marrow, and tonsils. Location and the behavior of lymphomas separate them from leukemia.The malignancy starts and restricted to lymphoid tissues and progress to involve the BM and appears in PB, at this stage it may be named, “lymphosarcoma cell leukemia.
B. Myelodysplastic syndrome (MDS) is the most likely diagnosis. MDS is characterized by dysplastic cells of all three lineages in the bone marrow, leading to peripheral cytopenias. The findings of macrocytic anemia, thrombocytopenia, and Pelger-Huet neutrophils on blood film are consistent with MDS. The bone marrow biopsy also showed a normocellular marrow. MDS commonly presents in the elderly and has no known cause in many cases.
This document discusses Hodgkin's lymphoma and non-Hodgkin's lymphoma. It defines lymphomas as solid tumors of the lymphatic system that are divided into two main types: Hodgkin's lymphoma, characterized by Reed-Sternberg cells, and non-Hodgkin's lymphoma, which lacks these cells. Signs and symptoms, risk factors, investigations, staging, and treatment approaches are described for both types of lymphoma.
Key coagulation disorders covered in this document include hemophilia A caused by a factor VIII deficiency, hemophilia B from a factor IX deficiency, and von Willebrand disease where von Willebrand factor is defective
Non-Hodgkin's lymphomas are cancers that develop from lymphocytes. They are distinguished from Hodgkin's lymphoma by the absence of Reed-Sternberg cells. The cause is often genetic mutations or translocations that affect cell growth and survival. Symptoms depend on the type and location of the tumor. Biopsy and testing are needed for diagnosis and to classify the specific lymphoma. Treatment options include chemotherapy, radiation therapy, immunotherapy, and stem cell transplants. Prognosis depends on factors like tumor stage, grade, the patient's age and health. Common types of non-Hodgkin's lymphoma include diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
What is Lymphoma?
Malignant lymphoma is a term given to tumors of the lymphoid system and specifically of lymphocytes and their precursor cells
i.e.
Cancer of the lymphatic system.
Many lymphomas are known to be due to specific genetic mutations.
This document provides an overview of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). It discusses the definition, epidemiology, risk factors, signs/symptoms, diagnosis, classification, and treatment of HL. It also discusses the overview, epidemiology, etiology, classification, and treatment of several common subtypes of NHL, including follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. Treatment options discussed include chemotherapy regimens like ABVD, R-CHOP, radiotherapy, immunotherapy with rituximab, and newer targeted therapies.
Molecular pathology of lymphoma by dr ramesh Ramesh Purohit
Lymphoma classification is based on the cell of origin (B-cell, T-cell, NK-cell). Molecular biology techniques including immunophenotyping and genetic studies are important for accurate diagnosis and classification. Immunophenotyping uses cell surface markers identified by clusters of differentiation (CD markers) to determine the cell lineage and stage of differentiation. Common CD markers for B-cells, T-cells, myeloid cells and other lineages are described. Molecular studies can identify genetic abnormalities that help classify specific lymphoma subtypes. Together these molecular techniques provide crucial information beyond what is visible by microscopy alone.
Hodgkin's lymphoma accounts for about 30% of malignant lymphomas. It originates in the lymphatic system and was first described by Thomas Hodgkin in 1832. There are four main subtypes: nodular lymphocyte predominant, nodular sclerosing, mixed cellularity, and lymphocyte depleted. It typically presents as painless, enlarged lymph nodes and has a bimodal age distribution, most commonly affecting those aged 25-30 and over 55. Staging involves imaging such as CT and PET scans to determine the extent of disease. Treatment depends on the stage but commonly involves chemotherapy, radiation, or a combination. Prognosis is generally good even for advanced stages.
Hodgkin's lymphoma is a type of cancer that originates from white blood cells called lymphocytes. It is characterized by the presence of abnormal Reed-Sternberg cells in the lymph nodes and other tissues. There are two main classifications - classical Hodgkin's lymphoma, which has four subtypes based on the appearance of the lymph nodes, and nodular lymphocyte predominant Hodgkin's lymphoma. Signs and symptoms include enlarged lymph nodes, night sweats, weight loss, and fever. The cause is unknown but may involve abnormal B cells that do not die normally.
Von Willebrand disease is a bleeding disorder caused by low levels of the clotting protein von Willebrand factor. There are three main types of the disease - type 1 involves a small amount of von Willebrand factor present, type 2 involves normal levels but defects in function/structure, and type 3 involves no von Willebrand factor present. Symptoms include easy bruising, excessive bleeding, and heavy menstrual periods. The disease is usually inherited and testing involves bleeding time, factor VIII levels, and von Willebrand factor specific tests. Treatment focuses on avoiding aspirin/NSAIDs and using drugs like DDAVP or clotting factor replacements.
This document discusses hemostasis, bleeding disorders, and platelet disorders. It begins by explaining normal hemostasis and the mechanisms involved in maintaining a fluid blood state and forming clots at sites of injury. It then defines bleeding disorders as problems with blood clotting that result in abnormal bleeding. Common causes discussed include defects in blood vessels or blood itself, clotting factor deficiencies, platelet abnormalities, and liver disease. Finally, it examines several specific platelet disorders like thrombocytopenia, immune thrombocytopenic purpura, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, and those resulting from bone marrow infiltration or disseminated intravascular coagulation.
Identified in 1921 by James Ewing
2nd most common bone tumor in children
Ewing’s Sarcoma Family of tumors:
Ewing’s sarcoma (Bone –87%)
Extraosseous Ewing’s sarcoma (8%)
Peripheral PNET(5%)
Askin’s tumor
This document discusses neoplasms of hematopoietic tissue, specifically leukemias and lymphomas. It describes that leukemias can be acute or chronic based on cell maturity and type (myelogenous or lymphogenous). The main types of leukemia are further classified as acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. Lymphomas include Hodgkin's lymphoma characterized by Reed-Sternberg cells, and non-Hodgkin's lymphomas which originate from B cells, T cells, or histiocytes and can be low, intermediate, or high grade. Burkitt's lymphoma originates from B cells and can be endemic or sporadic
This document discusses coagulation disorders and provides information on hemophilia A, hemophilia B, and disseminated intravascular coagulation (DIC). It notes that hemophilia A is an X-linked bleeding disorder caused by a deficiency in coagulation factor VIII, while hemophilia B is caused by a deficiency in factor IX. Von Willebrand disease is described as the most common inherited bleeding disorder involving a quantitative or qualitative abnormality of von Willebrand factor. DIC is defined as an acquired syndrome characterized by systemic intravascular coagulation that can lead to thrombosis and bleeding complications.
This document summarizes quantitative and qualitative platelet disorders. The most common causes of abnormal bleeding are decreased platelet production, survival, or increased destruction/consumption. Disorders can be congenital or acquired and involve decreased megakaryocyte production, BM infiltration, ineffective thrombopoiesis, or disorders of thrombopoiesis control. Increased platelet destruction can be immunologic due to ITP, drugs, transfusion, or non-immunologic consumption. Functional platelet disorders involve adhesion, aggregation, or secretion defects which may be hereditary or acquired.
Non-Hodgkin's lymphoma is a cancer of the lymphatic system that can affect B-cells or T-cells. It is classified based on the type of cell and aggressiveness. Common symptoms include swollen lymph nodes, fever, night sweats, and unintended weight loss. While the exact causes are unknown, risk factors include chemical exposure, infections, and immunodeficiency. Diagnosis involves imaging tests and biopsy. Treatment options include chemotherapy, radiation, immunotherapy, and bone marrow transplants, with survival rates varying based on cell type and staging.
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature-appearing B lymphocytes in the blood, bone marrow, lymph nodes, and spleen. It is considered a clonal B cell malignancy caused by a defect in apoptosis that allows long-lived, non-cycling lymphocytes to accumulate over time. CLL cells typically express CD5, CD19, and CD23 and have mutations that dysregulate pathways controlling cell survival and apoptosis. Prognosis depends on clinical features and genetic abnormalities - deletion of 13q or mutated IgVH correlate with better prognosis while deletion of 11q or 17p indicate poorer prognosis. CLL can transform into an aggressive lymphoma called Richter's syndrome over time.
Acute leukemias are malignant disorders of hematopoietic tissues characterized by increased white blood cells in the bone marrow and blood. They are classified as either acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) based on the affected cell lineage. Treatment involves chemotherapy to induce remission through combination regimens, with the goals of restoring normal hematopoiesis and preventing relapse through additional consolidation therapy and long-term maintenance treatment. Prognosis depends on several risk factors like age, subtype, initial response to treatment, and specific genetic abnormalities.
1. The document discusses common benign and malignant pediatric tumors, including hemangiomas, neuroblastoma, Wilms tumor, and teratomas.
2. Neuroblastoma is the most common extracranial solid tumor in childhood and often presents as an abdominal mass, fever, or weight loss in children under 2.
3. Wilms tumor is the most common renal tumor of childhood, occurring mostly in ages 2-5, and may be associated with genetic syndromes like WAGR or Beckwith-Wiedemann syndrome.
Pathogenesis and treatment of Chronic Myeloid LeukemiaAlok Gupta
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome and BCR-ABL fusion gene. The natural history involves chronic, accelerated, and blast crisis phases if untreated. Tyrosine kinase inhibitors (TKIs) like imatinib revolutionized CML treatment by targeting BCR-ABL. TKIs induce high rates of response but resistance and intolerance occur in some patients. For these cases, second-generation TKIs or allogeneic stem cell transplant are recommended. Advanced phase CML has a poorer prognosis but TKIs can induce responses before transplant, which offers the best chance of cure.
This document provides information on chronic myelogenous leukemia (CML), including its definition, history, epidemiology, etiology, pathogenesis, clinical features, diagnosis, disease course, treatment, and more. Some key points:
- CML is a stem cell disease characterized by increased white blood cells, anemia, splenomegaly, and the Philadelphia chromosome.
- It has three phases: chronic, accelerated, and blast crisis. Treatment depends on the phase and may include tyrosine kinase inhibitors like imatinib, interferon, chemotherapy, and stem cell transplantation.
- The disease is caused by the BCR-ABL fusion gene which results in uncontrolled tyrosine kinase activity and increased proliferation of
Lymphoma is a cancer of lymphocytes. The most common place for abnormal lymphocytes is in lymph nodes (glands) particularly
under the arms, in the neck and in the groin.
Lymphoma is solid tumors of the immune system arising from cells of lymphoid tissues; lymphocytes, histiocytes, and reticulum cells. It can happen anywhere in the immune system, but usually in lymph nodes, spleen, marrow, and tonsils. Location and the behavior of lymphomas separate them from leukemia.The malignancy starts and restricted to lymphoid tissues and progress to involve the BM and appears in PB, at this stage it may be named, “lymphosarcoma cell leukemia.
B. Myelodysplastic syndrome (MDS) is the most likely diagnosis. MDS is characterized by dysplastic cells of all three lineages in the bone marrow, leading to peripheral cytopenias. The findings of macrocytic anemia, thrombocytopenia, and Pelger-Huet neutrophils on blood film are consistent with MDS. The bone marrow biopsy also showed a normocellular marrow. MDS commonly presents in the elderly and has no known cause in many cases.
Mr. Salim, a 62-year-old man, presented with right neck and left groin swelling for 3 months along with 7-8 kg of weight loss. Biopsy revealed diffuse large B-cell non-Hodgkin lymphoma (NHL). He was diagnosed with stage IV NHL and treated with rituximab and CHOP chemotherapy. The presentation discusses lymphadenopathy causes, lymphoma types and differences between Hodgkin and non-Hodgkin lymphomas, risk factors, investigations and treatments. Key points include distinguishing reactive from tumoral lymph nodes, indolent versus aggressive NHL subtypes, common genetic abnormalities in lymphomas, and involvement of Epstein-Barr virus in certain malignancies.
1. Lymphoma refers to cancers that develop from lymphocytes in the lymph nodes and other lymphoid tissues. The document discusses the classification, clinical features, pathogenesis, and pathology of various types of lymphoma including Hodgkin lymphoma and non-Hodgkin lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and Burkitt lymphoma.
2. Hodgkin lymphoma is characterized by the presence of Reed-Sternberg cells amidst an inflammatory background. The four major histologic subtypes are nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte rich classical Hodgkin lymphoma.
3. Non-
Lymphoid proliferations can be benign or malignant. Benign causes include infections while malignant causes include lymphomas. Lymphomas are divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma. Hodgkin's lymphoma is characterized by Reed-Sternberg cells while non-Hodgkin's lymphoma can be of B-cell or T-cell origin. Investigation of lymph node enlargement includes history, examination, blood tests, imaging and biopsy to determine if the cause is benign reactive hyperplasia, infection, or malignancy such as lymphoma or metastatic carcinoma.
Lymphoid proliferations can be benign or malignant. Benign causes include infections while malignant causes include lymphomas. Lymphomas are divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma. Hodgkin's lymphoma is characterized by Reed-Sternberg cells while non-Hodgkin's lymphoma can be of B-cell or T-cell origin. Different cell markers are used to identify the specific cell type by flow cytometry and immunohistochemistry. Investigation of lymph node enlargement includes history, examination, blood tests, imaging and biopsy to determine if the cause is benign reactive hyperplasia or malignant lymphoma or metastatic carcinoma.
This document provides an overview of lymphomas and chronic lymphocytic leukemia (CLL). It defines lymphomas as malignant proliferation of lymphocytes accumulating in lymph nodes and tissues. It describes classification systems for lymphomas and discusses Hodgkin's lymphoma and non-Hodgkin's lymphoma in terms of characteristics, investigation, diagnosis, treatment and complications. It also discusses CLL, describing its pathophysiology, clinical features, investigation, natural history and treatment options.
An array of presentation of lymphoma spillover in the peripheral smear and bone marrow. All types of lymphomas are discussed along with a bouquet of HPE pictures
This document discusses lymphoproliferative disorders, which include lymphomas and leukemias characterized by excessive lymphocyte production. It defines key lymphoproliferative disorders like lymphoma, leukemia, chronic lymphocytic leukemia, and provides information on infectious mononucleosis, Burkitt's lymphoma, follicular lymphoma, and Hodgkin and non-Hodgkin lymphomas including their causes, clinical features, diagnostic criteria, staging systems, and treatment approaches.
This document provides information on Non-Hodgkin Lymphoma (NHL), including its subtypes, risk factors, clinical presentation, staging, diagnostic evaluation, and treatment approaches. NHL is a heterogeneous group of malignancies of the lymphoid system. Diffuse large B-cell lymphoma is the most common subtype. Staging involves physical exam, labs, imaging like CT and PET scans. Treatment depends on stage and risk factors, and may involve chemotherapy like R-CHOP with or without radiation therapy. Outcomes are based on prognostic scores like IPI and response to initial treatment.
Lymphoma by Sunil Kumar Daha (Hodgkins and Non-Hodgkins)sunil kumar daha
Please find the power point onLymphoma . I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
This document discusses lymphomas, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. It covers the classification, pathogenesis, clinical features, investigations, and treatment of these conditions. Key points include: lymphomas are malignant tumors of lymphoreticular tissues, Hodgkin's lymphoma is characterized by the presence of Reed-Sternberg cells, classifications include Rye and WHO systems, clinical features depend on location and include enlarged lymph nodes and systemic symptoms, investigations involve imaging, biopsies and blood tests, and treatment involves chemotherapy, radiation therapy, bone marrow transplants or supportive care.
Non-Hodgkin's lymphomas arise from monoclonal expansion of malignant B or T cells. There are many subtypes of NHL, classified based on cell lineage and other features. Treatment depends on factors like aggressiveness - indolent NHLs grow slowly while very aggressive NHLs can be life-threatening if not treated rapidly. The most common subtypes are diffuse large B-cell lymphoma and follicular lymphoma. Diagnosis involves biopsy and other tests to identify the histologic subtype and stage of disease. Prognosis and treatment approach are guided by these factors.
Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the proliferation of immature lymphocytes in the bone marrow. Diagnosis requires identifying at least 20% lymphoblasts in the bone marrow. Testing includes bone marrow biopsy and aspiration with immunophenotyping, cytogenetics, lumbar puncture and other studies. Proper classification is important for determining prognosis and selecting optimal treatment strategies.
Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD);Flowcytometric...Dr Siddartha
Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD);Flowcytometric Evaluation
Basavatarakam Indo-American Cancer Hospital and Research Institute
This document discusses the case of a 35-year-old female patient presenting with fever, fatigue, and shortness of breath. Her medical history includes a hysterectomy for menorrhagia and treatment for genitourinary tuberculosis. On examination, she has pallor and tachycardia. Laboratory tests show pancytopenia and blasts in her peripheral blood smear. A bone marrow biopsy confirms the diagnosis of acute myeloid leukemia. The discussion reviews the epidemiology, etiology, classification, clinical presentation, diagnostic workup, and initial treatment evaluation for AML.
1. Lymphoma is the third most common childhood cancer and is broadly categorized into Hodgkin's disease and non-Hodgkin's lymphoma.
2. Hodgkin's disease is characterized by Reed-Sternberg cells and is further classified under Rye or REAL systems. Common subtypes include lymphocyte predominant, mixed cellularity, and nodular sclerosis.
3. Non-Hodgkin's lymphoma in children includes subtypes like Burkitt's lymphoma, lymphoblastic lymphoma, diffuse large B-cell lymphoma, and anaplastic large cell lymphoma.
1. Lymphoma refers to cancers that develop from lymphocytes, a type of white blood cell.
2. The document discusses the classification, signs and symptoms, diagnosis, and origins of several types of lymphoma including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and mantle cell lymphoma.
3. It also covers Hodgkin lymphoma, marginal zone lymphoma, mantle lymphoma, and hairy cell leukemia providing details on their clinical features and pathogenesis.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
2. Lymphoma
• Clonal malignant disorders that are derived from
lymphoid cells: either precursor or mature T-cell
or B-cell
• Majority are of B- cell origin
• Divided into 2 main types :
1. Hodgkin’s lymphoma
2. Non - Hodgkin’s lymphoma
3. Blood Cell and Lymphocyte
Development
STEM CELLS
Multipotential
myeloid cells
Multipotential
lymphocytic cells
Differentiate & mature into 6
Types of blood cells
red cells basophils
neutrophils monocytes
eosinophils platelets
Differentiate & mature into 3
Types of lymphocytes
T lymphocytes
B lymphocytes
Natural Killer Cells
4. T-Cells and B-Cells
Immature lymphocytes that travel to the
thymus differentiate into T-Cells
– “T” is for thymus
Immature lymphocytes that travel to the
spleen or lymph nodes differentiate into B
cells
– "B" stands for the bursa of Fabricius, which is
an organ unique to birds, where B cells
mature.
7. A 25 year old lady
1 month of evening rise of temperature, night
sweats and noticed a lump in her neck
On examination pallor, generalized
lymphadenopathy, hepatosplenomegaly
12. Clinical features
• Bimodal age distribution :
– young adults ( 20-30 yrs) & elderly (> 50yrs) May
occur at any age
• M > F
• Lymphadenopathy:
– most often cervical region
– asymmetrical, discrete
– painless, non-tender
– elastic character on palpation ( rubbery)
– not adherent to skin
– fluctuate in size
13. • Contiguous spread via the lymphatic chain
eg.involvement of abdominal & thoracic LNs
• Extra nodal disease - rare
• Hepatospleenomegaly
14. • Constitutional symptoms ( B symptoms )
–Night sweats,
–sustained fever > 38 degree celsius,
–loss of weight >10% of body weight in 6 mo
• Fever sometimes cyclical (‘Pel-Ebstein fever’)
• Pain at the site of disease after drinking alcohol
• Pallor
• Pruritis
• Symptoms of Bulky (>10 cm) disease
16. • LN FNAC / biopsy :
– Malignant REED-STERNBERG ( RS) Cell: Bi-nucleate cell
with a prominent nucleolus. Derived from B cell, at an
early stage of differentiation
– Reactive background of eosinophils, lymphocytes,
plasma cells
– Fibrous tissue
25. Staging
• Stage I : Involvement of single LN region (I) or extra
lymphatic site (IAE )
• Stage II : Two or more LN regions involved (II) or an extra
lymphatic site and lymph node regions on the same side of
diaphragm
• Stage III : Involvement of lymph node regions on both sides
of diaphragm, with (IIIE) or without (III) localized extra
lymphatic involvement or involvement of the spleen (IIS) or
both (IISE)
• Stage IV : Involvement outside LN areas (Liver, bone
marrow)
A : Absence of ‘B’ symptoms
B : B symptoms present
26.
27. Treatment - Guidelines
• Indications for RT:
– Stage I disease
– Stage II disease with 3 or lesser areas involved
– For Bulky disease
– For pressure problems
• Indications for CT
– All with B symptoms
– Stage II disease with >3 areas involved
– Stage III and IV disease
28. Treatment
• Stage IA , Stage IIA with 3 or < 3 areas involved:
Radiotherapy
• Stage IB, Stage II A with > 3 areas , Stage IIB:
Chemotherapy every 3-4 weeks, 6-8 cycles; either
alone, or in combination with radiotherapy
• Stage III & IV : Chemotherapy +
Radiotherapy ( for bulky disease or palliation of
symptoms)
30. Chemotherapy
• MOPP :
Nitrogen Mustard,
Vincristine (Oncovin),
Procarbazine,
Prednisolone
• ABVD:
Adriamycin,
Bleomycin,
Vinblastine,
Dacarbazine
• Higher dose for relapse or younger pts with poor
prognostic features
31. Prognosis
• Overall 10 yr survival – 80%
• In long term survivors there is a risk of
– secondary malignancy: (leukemia , NHL), Solid tumors-
Lung, breast
– Infections
– Cardiac, pulmonary, endocrinal abnormalities
32. International Prognostic Index (IPI)
• Age
• Advanced stage disease
• Performance status
• Elevated LDH
• Presence of Extra nodal disease
33. Non Hodgkin’s lymphoma
• Incidence is increasing
• NHL>HD
• Median age of presentation is 65-70 yrs
• M>F
• More often clinically disseminated at
diagnosis
• B-cell-70% ; T-cell-30%
34. Relative frequencies of different
lymphomas
Hodgkin
lymphoma
NHL
Diffuse large B-cell
Follicular
Other NHL
Non-Hodgkin Lymphomas
~85% of NHL are B-lineage
35. Specific types
• Precursor B cell lymphoblastic
leukemia/lymphoma
Most common cancer in chilhood is B cell ALL
36. Cells are hetrogenous insize and
round/convoluted nuclei,high
nuclear/cytoplasmic ratio and absence of
cytoplasmic granules
39. • Young pt-bone marrow transplatation
• Chlorambucil alone or with cyc,rituximab
• Fludarabine
• CVP-CYC,VINCRISTINE
40. MALT-LYMPHOMA
Extra nodal marginal zone
Associated with H.pylori
CD-5 negative
Can occur in
stomach,orbit,intestine,lung,thyroid,salivary
gland,skin,soft tissue,bladder,kidney,CNS
44. irregular nuclear contours of the medium-sized lymphoma cells and the presence of a
pink histiocyte. By immunohistochemistry the lymphoma cells expressed CD20, CD5
and Cyclin D1
46. • Classic appearance of spleen involved by
follicular lymphoma, namely the presence of
discrete, miliary, small, white "pearly" nodules
throughout the whole parenchyma.
52. BURKITT’S LYMPHOMA
• RARE
• T(8;14)
• T(2;8),C-MYC and LAMDA LIGHT CHAIN GENE
• HIV Associated
• Most rapidly progressive human tumour
53.
54.
55.
56. • The "starry sky" appearance seen under low
power is due to scattered tingible body-laden
macrophages (macrophages containing dead
apoptotic tumor cells).
57. Hairy cell leukemia
• B –CELL
• Presents as Pancytopenia
• Hairy projections on light/electron microscopy
66. • A 22-year-old female presented with 2 weeks
of fever, anemia, generalized
lymphadenopathy, hepatosplenomegaly, and
skin rashes. Her total leukocyte count was 306
× 109/L. Peripheral blood smear showed many
atypical lymphocytes with petal-shaped nuclei
like flowers as seen in the photograph..
68. • Peripheral blood immunophenotype noted
negative markers for myeloid and B lymphoid
lineage (CD10, CD19, CD3, CD5, CD7, cyto-
CD3, TCR, CD16, CD56) and strongly positive
for CD4 and CD25, and also CD2, which was
atypical. Bone marrow aspirate and biopsy
revealed involvement by acute leukemia.
Serology for HTLV-1 was positive and serum
calcium was normal
69. Anaplastic large T/null cell lymphoma
• ALK-ANAPLASTIC LYMPHOMA KINASE protein
positive
• t(2;5)
• CD-30 POSITIVE
73. • A 38-year-old lady was referred for FNAC of
multiple left axillary nodes, one of them in the
axillary tail of left breast, which appeared as a
breast lump in the upper outer quadrant. The
nodes ranged from 1 to 3 cm in size, were well
defined, mobile, firm and non-tender. s
74. • There were no systemic symptoms and no
other organomegaly. Peripheral blood counts
and erythrocyte sedimentation rate (ESR)
were within normal limit
75. Section of lymph node containing
vascularized germinal centres and
eosinophilic material
76. Rosai dorfman disease
• Rosai–Dorfman disease, also known as sinus
histiocytosis with massive lymphadenopathy,
is a rare disorder of unknown cause that is
characterized by abundant histiocytes in the
lymph nodes throughout the body.
77.
78. ONE WORD ANSWER
• FLOWER CELLS SEEN IN-
• BASKET CELLS SEEN IN-
• T(14;18) seen in-
• STARRY SKY PATTERN SEEN IN-
• Mycosis fungoides is ……T/B cell lymphoma
• CD 15 AND CD 30 NOT SEEN IN……HODGKINS
TYPE LYMPHOMA